{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-238564","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2024-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.187086+00:00","generated_at":"2026-05-30T13:31:18.700683+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Delcath reports preliminary Q3 revenue $11.2M; HEPZATO KIT sales trigger $25M warrant exercise","bullets":["Preliminary Q3 2024 revenue of $11.2M, including $10M U.S. sales from HEPZATO KIT.","Announcement of $10M U.S. quarterly revenue triggers exercise of Tranche B warrants from March 2023 PIPE.","Warrant holders have 21 days to exercise at $6/share for aggregate $25M.","Proceeds to support HEPZATO KIT commercial launch and fund new clinical trials for expanded indications.","Final Q3 results and business update scheduled for investor call on November 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-238564","json":"https://secwatch.observer/filing/0001193125-24-238564.json","markdown":"https://secwatch.observer/filing/0001193125-24-238564.md","text":"https://secwatch.observer/filing/0001193125-24-238564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000119312524238564/0001193125-24-238564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000119312524238564/d837829d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:31:18.700683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}